

## PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Dmitriy Zamarin, ... , Taha Merghoub, Jedd D. Wolchok

*J Clin Invest.* 2018;128(11):5184-5184. <https://doi.org/10.1172/JCI125039>.

### Corrigendum

Original citation: *J Clin Invest.* 2018;128(4):1413–1428. <https://doi.org/10.1172/JCI98047> Citation for this corrigendum: *J Clin Invest.* 2018;128(11):5184. <https://doi.org/10.1172/JCI125039> Jedd D. Wolchok's conflict-of-interest information was incomplete. The omitted statement is below. JDW has acted as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, BeiGene, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical Co., Elucida Oncology Inc., Eli Lilly and Company, F-Star, Genentech, Imvaq Therapeutics Corp., Kleo Pharmaceuticals, MedImmune, Merck, Neon Therapeutics, Ono Pharmaceutical Co., Polaris Pharma, Polynoma, PsiOxus Therapeutics, PureTech Health, Recepta Biopharma SA, Trieza Therapeutics, Sellas Life Sciences, Seramatrix Immune Monitoring, Surface Oncology, and Syndax; has received research support from Bristol-Myers Squibb, MedImmune, Merck, Genentech; and has equity in Potenza Therapeutics (cofounder), Tizona Therapeutics (cofounder), Adaptive Biotechnologies, Elucida Oncology Inc., Imvaq Therapeutics Corp., BeiGene, and TriEnza. The authors regret the error.

**Find the latest version:**

<https://jci.me/125039/pdf>



## Corrigendum

### PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Dmitriy Zamarin, Jacob M. Ricca, Svetlana Sadekova, Anton Oseledchik, Ying Yu, Wendy M. Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, and Jedd D. Wolchok

Original citation: *J Clin Invest.* 2018;128(4):1413–1428. <https://doi.org/10.1172/JCI98047>.

Citation for this corrigendum: *J Clin Invest.* 2018;128(11):5184. <https://doi.org/10.1172/JCI125039>.

Jedd D. Wolchok's conflict-of-interest information was incomplete. The omitted statement is below.

JDW has acted as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, BeiGene, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical Co., Elucida Oncology Inc., Eli Lilly and Company, F-Star, Genentech, Imvq Therapeutics Corp., Kleo Pharmaceuticals, MedImmune, Merck, Neon Therapeutics, Ono Pharmaceutical Co., Polaris Pharma, Polynoma, PsiOxus Therapeutics, PureTech Health, Recepta Biopharma SA, Trieza Therapeutics, Sellas Life Sciences, Seramatrix Immune Monitoring, Surface Oncology, and Syndax; has received research support from Bristol-Myers Squibb, MedImmune, Merck, Genentech; and has equity in Potenza Therapeutics (cofounder), Tizona Therapeutics (cofounder), Adaptive Biotechnologies, Elucida Oncology Inc., Imvq Therapeutics Corp., BeiGene, and TriEnza.

The authors regret the error.

## Corrigendum

### IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in *ApoE*<sup>-/-</sup> mice

Jing Wang, Xiang Cheng, Mei-Xiang Xiang, Mervi Alanne-Kinnunen, Jian-An Wang, Han Chen, Aina He, Xinghui Sun, Yan Lin, Ting-Ting Tang, Xin Tu, Sara Sjöberg, Galina K. Sukhova, Yu-Hua Liao, Daniel H. Conrad, Lunyin Yu, Toshiaki Kawakami, Petri T. Kovanen, Peter Libby, and Guo-Ping Shi

Original citation: *J Clin Invest.* 2011;121(9):3564–3577. <https://doi.org/10.1172/JCI146028>.

Citation for this corrigendum: *J Clin Invest.* 2018;128(11):5184. <https://doi.org/10.1172/JCI124107>.

The representative panels shown in Figure 5B are incorrect. The correct panels are below.

The authors regret the error.

